Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13992)	1/30/1998 10:56:00 PM
From: DrJerry	Respond to of 32384

HENRY: Attended a diabetes forum tonight- the consensus across the country is that the market is so huge that any new drug of significance will do well. almost all experts are treating patient with sugars between 126-140 with drugs for the insulin resistance syndrome. The only 2 real contenders are Rezulin (a TZD) amd BMS drug glucophage (metformin). The rezulin markeet is in no way less because of the Glaxo removal in the UK- everyone is aware of Glaxos TZD which is not far from release. At any rate if there is a rexinoid which is synergistic we are looking at a market which will dwarf that of drugs for KS etc. More warrants for me!